Price T Rowe Associates Inc. MD Sells 1,572,074 Shares of Hologic, Inc. (NASDAQ:HOLX)

Price T Rowe Associates Inc. MD cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 56.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,229,855 shares of the medical equipment provider's stock after selling 1,572,074 shares during the period. Price T Rowe Associates Inc. MD owned 0.54% of Hologic worth $88,661,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Benson Investment Management Company Inc. bought a new stake in shares of Hologic during the 4th quarter valued at $4,832,000. Principal Financial Group Inc. increased its position in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after buying an additional 1,606 shares during the period. Clean Yield Group lifted its holdings in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after buying an additional 7,266 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after acquiring an additional 238,222 shares during the period. Finally, Nordea Investment Management AB grew its stake in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after acquiring an additional 544,889 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Trading Down 5.4 %

Shares of NASDAQ:HOLX traded down $3.12 during trading on Friday, reaching $54.16. 7,843,345 shares of the company traded hands, compared to its average volume of 2,005,628. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $52.12 and a 52-week high of $84.67. The firm has a market capitalization of $12.15 billion, a price-to-earnings ratio of 17.09, a P/E/G ratio of 2.14 and a beta of 0.54. The business's fifty day moving average is $60.28 and its 200-day moving average is $69.17.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.03 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Evercore ISI reduced their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Friday. Royal Bank of Canada cut their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday. Finally, Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and an average target price of $81.15.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.